ClinicalTrials.gg

Program

Hadlima

Its studies are led by Biora Therapeutics.

Furthest: phase 1, since Sep 24, 20261 company-led study, 1 open or runningNext primary completion: Jan 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biora Therapeutics11 open or runningphase 1since Sep 24, 2026Sep 24, 2026Jan 15, 2027phase 1 · NCT07849153

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 24, 2026First study: phase 1 study in Healthy SubjectsFirst studyNCT07849153 · 30 planned

Ahead

  1. Jan 15, 2027Primary completion: phase 1 study in Healthy SubjectsNCT07849153

TargetBeta

TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule

Other programs on TNF

ProgramCompanyFurthest phaseStudies
AdalimumabruleAbbottphase 4153
Brentuximab VedotinrulePfizerphase 437
CHS-1420rulenanjing-king-friend-biochemical-pharmaceutical-co-ltdphase 32
brivekimigSanofiphase 26

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07849153Healthy Subjects1Not yet recruitingJan 15, 202730

How it is read

Names in the registry

  • “Hadlima®”, 3 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.